Frontline treatment with enfortumab vedotin/pembrolizumab is associated with the highest healthcare costs for patients with locally advanced or metastatic urothelial carcinoma.
The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.
Patients with nonmetastatic clinically node positive bladder cancer who wish to avoid major surgery may achieve similar clinical outcomes with trimodal therapy.